FORT LAUDERDALE, Fla., Aug. 25 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, announced today that their EDC tool, TrialMaster(TM), has been selected by Pleiad, Inc., a Cambridge, Massachusetts based Contract Research Organization (CRO) with European operations in the U.K., to provide eClinical services to its customers. Pleiad's investment will provide it with the products and services to manage two upcoming studies investigating the use of ophthalmic medical devices. This partnership is expected to generate more than $1 million to OmniComm over the next few years. Pleiad has worked with the TrialMaster EDC tool since April 2008 under OmniComm's CRO Preferred Program, and is now transitioning to a Technology Transfer model in order to provide greater value to its customers engaged in these important clinical trials.
"We are pleased to once again be collaborating with Pleiad, as the exposure generated from working closely on a continual basis with such a specialized, internationally renowned CRO will undoubtedly raise our profile within the international clinical community," commented Stephen Johnson, OmniComm's COO. "We expect that as we continue to work with well respected, high profile organizations such as Pleiad, we will continue to attract companies of an equally high caliber to our dramatically enhanced service offering. We feel that we can offer organizations engaged in clinical research a significant advantage over their peers with our highly specialized portfolio of eClinical solutions designed to greatly simplify the clinical process."
"TrialMaster has been an essential option for us to provide to our customers. Much is made about the importance of subject compliance in clinical research, but we find that study coordinator 'compliance' is also very critical. The TrialMaster EDC system is very intuitive, so the study coordinators with whom we work have little problem in getting their work completed within the allocated time," stated Stephen Brandao, Pleiad's Vice President of Business Development. "We find that OmniComm is an attentive partner, very much in tune with the needs of our business. Our team anticipates collaborating with them on future opportunities."
Pleiad, Inc. is a clinical CRO (contract research organization) that specializes in expertly assisting medical device, combination, women's health, and ophthalmic product manufacturers meet the clinical, quality, safety and regulatory requirements of the product development process. Their work encompasses the progression from the conceptual and developmental stages to post-marketing trials, offering regulatory support, clinical trial management, and safety monitoring services.
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Catherine Lemercier OmniComm Systems, Inc. 954-473-1254 Extension 283 email@example.com Stephen Johnson at: + 1 954-377-1726 Gary Nash CEOcast, Inc. for OmniComm 212-732-4300 firstname.lastname@example.org
|SOURCE OmniComm Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved